The Zijlstra Lab is looking for a postdoctoral fellow to pursue the analysis of extracellular vesicles (EV) that mediate tumor-host communication during tumor progression to metastatic disease. Research in the laboratory is focused on understanding the molecular and cellular underpinnings of metastatic dissemination. The lab has succeeded in merging computational and wet-lab technologies to accelerate research progress. The result is a research environment in which multiparametric and quantitative analysis of experimental systems and clinical specimens drive our emerging understanding of tumor-host interactions. This project is particularly focused on the regulation of tumor-host interaction EV and will leverage newly developed single-EV analysis developed in the Zijlstra Lab while leveraging the unique resources of Genentech to identify the mechanism of action by which EV facilitate tumor progression.

Responsibilities will include contributing to the overall research strategy, designing and conducting experiments, analyzing data, preparing and presenting research findings at meetings, leading or contributing to the writing of scientific manuscripts. In addition, the successful candidate is expected to engage peers in the emerging EV community of Genentech and leverage synergies across the collaborating laboratories.

Duration: 4 years

Genentech has a postdoctoral fellow program focused on collaboration, mentorship, networking, and recognition. For more information about this program please visit:  https://careers.gene.com/us/en/students-postdocs .

Relevant Publications:
Mariscal J, Vagner T, Kim M, Zhou B, Chin A, Zandian M, Freeman MR, You S, Zijlstra A, Yang W, Di Vizio D. Comprehensive palmitoyl-proteomic analysis identifies distinct protein signatures for large and small cancer-derived extracellular vesicles. J Extracell Vesicles. 2020 Jun 10;9(1):1764192. doi: 10.1080/20013078.2020.1764192.

Hebron KE, Li EY, Arnold Egloff SA, von Lersner AK, Taylor C, Houkes J, Flaherty DK, Eskaros A, Stricker TP, Zijlstra A. Alternative splicing of ALCAM enables tunable regulation of cell-cell adhesion through differential proteolysis. Sci Rep. 2018 Feb 16;8(1):3208. doi: 10.1038/s41598-018-21467-x.

Sung BH, von Lersner A, Guerrero J, Krystofiak ES, Inman D, Pelletier R, Zijlstra A, Ponik SM, Weaver AM. A live cell reporter of exosome secretion and uptake reveals pathfinding behavior of migrating cells. Nat Commun. 2020 Apr 29;11(1):2092. doi: 10.1038/s41467-020-15747-2.

Reis-Sobreiro M, Chen JF, Novitskaya T, You S, Morley S, Steadman K, Gill NK, Eskaros A, Rotinen M, Chu CY, Chung LWK, Tanaka H, Yang W, Knudsen BS, Tseng HR, Rowat AC, Posadas EM, Zijlstra A, Di Vizio D, Freeman MR. Emerin Deregulation Links Nuclear Shape Instability to Metastatic Potential. Cancer Res. 2018 Nov 1;78(21):6086-6097. doi: 10.1158/0008-5472.CAN-18-0608. Epub 2018 Aug 28.

Arnold Egloff SA, Du L, Loomans HA, Starchenko A, Su PF, Ketova T, Knoll PB, Wang J, Haddad AQ, Fadare O, Cates JM, Lotan Y, Shyr Y, Clark PE, Zijlstra A. Shed urinary ALCAM is an independent prognostic biomarker of three-year overall survival after cystectomy in patients with bladder cancer. Oncotarget. 2017 Jan 3;8(1):722-741. doi: 10.18632/oncotarget.13546.

Note: Relocation benefits are available for this position

Genentech is an equal opportunity employer, and we embrace the increasingly diverse world around us. Genentech prohibits unlawful discrimination based on race, color, religion, gender, sexual orientation, gender identity or expression, national origin or ancestry, age, disability, marital status and veteran status.

Genentech requires all new hires to be fully vaccinated against COVID-19 as of their start date. This requirement is a condition of employment at Genentech, and it applies regardless of whether the position is located at a Genentech campus or is fully remote.  If you are unable to receive the vaccine due to a disability or serious medical condition, or because it is prohibited as a result of your sincerely held religious beliefs, you will have an opportunity to request a reasonable accommodation.